Mechanistic and Clinical Insights at the Scleroderma-cancer Interface

Overview

Journal J Scleroderma Relat Disord

Date 2017 Dec 22

PMID 29264402

Citations 15

Authors

Ami A Shah

Livia Casciola-Rosen

Affiliations

Soon will be listed here.

Abstract

Emerging data suggest tantalizing links between cancer and systemic inflammatory rheumatic syndromes. In scleroderma, patients may have an increased risk of cancer secondary to chronic inflammation and damage from the disease, malignant transformation promoted by immunosuppressive therapies, a shared susceptibility to both cancer and autoimmunity, or a common inciting exposure. However, it is increasingly recognized that a subset of patients develop cancer around the time that scleroderma clinically manifests, raising the question of cancer-induced autoimmunity. In this review, we discuss data suggesting a mechanistic link between cancer and the development of scleroderma, and the clinical implications of these findings.

Citing Articles

A Rare Lung Malignancy in a Case of Systemic Sclerosis.

C S, P H, Jayanthi N Cureus. 2024; 16(7):e65146.

PMID: 39176361 PMC: 11341069. DOI: 10.7759/cureus.65146.

Anti-Th/To Antibodies in Scleroderma: Good Prognosis or Serious Concern?.

Mozdzan M, Wegiel A, Biskup L, Brzezinska O, Makowska J J Clin Med. 2024; 13(11).

PMID: 38892733 PMC: 11172938. DOI: 10.3390/jcm13113022.

Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis.

Hoppner J, Tabeling C, Casteleyn V, Kedor C, Windisch W, Burmester G Front Immunol. 2023; 13:1045523.

PMID: 36685532 PMC: 9846214. DOI: 10.3389/fimmu.2022.1045523.

Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study.

Isca C, Spinella A, Toss A, de Pinto M, Ficarra G, Fabbiani L J Pers Med. 2022; 12(12).

PMID: 36556228 PMC: 9780893. DOI: 10.3390/jpm12122007.

Improving outcomes in scleroderma: recent progress of cell-based therapies.

Khanna D, Krieger N, Sullivan K Rheumatology (Oxford). 2022; 62(6):2060-2069.

PMID: 36355455 PMC: 10234204. DOI: 10.1093/rheumatology/keac628.

References

Onishi A, Sugiyama D, Kumagai S, Morinobu A . Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013; 65(7):1913-21. DOI: 10.1002/art.37969. View

Egiziano G, Bernatsky S, Shah A . Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol. 2016; 30(1):53-62. PMC: 4947510. DOI: 10.1016/j.berh.2016.03.001. View

Robson R, Cecka J, Opelz G, Budde M, Sacks S . Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005; 5(12):2954-60. DOI: 10.1111/j.1600-6143.2005.01125.x. View

Hashimoto A, Arinuma Y, Nagai T, Tanaka S, Matsui T, Tohma S . Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis. Intern Med. 2012; 51(13):1683-8. DOI: 10.2169/internalmedicine.51.7686. View

Liang Y, Yang Z, Qin B, Zhong R . Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2013; 73(6):1151-6. DOI: 10.1136/annrheumdis-2013-203305. View

De Angelis R, Bugatti L, Cerioni A, Del Medico P, Filosa G . Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol. 2003; 22(1):49-52. DOI: 10.1007/s10067-002-0635-8. View

Antonelli A, Ferri C, Ferrari S, Di Domenicantonio A, Giuggioli D, Galleri D . Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis. Rheumatology (Oxford). 2015; 55(3):480-4. DOI: 10.1093/rheumatology/kev358. View

Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento E, La Vecchia C . Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford). 2012; 52(1):143-54. DOI: 10.1093/rheumatology/kes303. View

Kasifoglu T, Yasar Bilge S, Yildiz F, Ozen G, Pehlivan Y, Yilmaz N . Risk factors for malignancy in systemic sclerosis patients. Clin Rheumatol. 2016; 35(6):1529-33. DOI: 10.1007/s10067-016-3288-8. View

10.

Kang K, Yim H, Kim I, Yoon J, Ju J, Kim H . Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol. 2009; 38(4):299-303. DOI: 10.1080/03009740802642062. View

11.

Finch W, Rodnan G, Buckingham R, PRINCE R, Winkelstein A . Bleomycin-induced scleroderma. J Rheumatol. 1980; 7(5):651-9. View

12.

Peters-Golden M, Wise R, Hochberg M, STEVENS M, Wigley F . Incidence of lung cancer in systemic sclerosis. J Rheumatol. 1985; 12(6):1136-9. View

13.

Juarez M, Marshall R, Denton C, Evely R . Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology (Oxford). 2008; 47(11):1734-5. DOI: 10.1093/rheumatology/ken367. View

14.

Frauenfelder T, Winklehner A, Nguyen T, Dobrota R, Baumueller S, Maurer B . Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study. Ann Rheum Dis. 2014; 73(12):2069-73. DOI: 10.1136/annrheumdis-2014-205637. View

15.

Shah A, Rosen A, Hummers L, May B, Kaushiva A, Roden R . Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clin Exp Rheumatol. 2017; 35 Suppl 106(4):71-74. PMC: 5947318. View

16.

Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin J, Petri M . Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013; 42:130-5. PMC: 3646904. DOI: 10.1016/j.jaut.2012.12.009. View

17.

Kuo C, Luo S, Yu K, Chou I, Tseng W, Chang H . Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol. 2011; 41(1):44-9. DOI: 10.3109/03009742.2011.618145. View

18.

Monach P, Arnold L, Merkel P . Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2009; 62(1):9-21. DOI: 10.1002/art.25061. View

19.

Dreyer L, Faurschou M, Mogensen M, Jacobsen S . High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 2011; 63(10):3032-7. DOI: 10.1002/art.30483. View

20.

Cappelli L, Gutierrez A, Bingham 3rd C, Shah A . Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken). 2016; 69(11):1751-1763. PMC: 5478477. DOI: 10.1002/acr.23177. View